← All trials
NCT03984370
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2019
- Primary completion
- Dec 15, 2019
- Completion date
- May 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 10
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CopenhagenLead sponsor
- University of CopenhagenReponsible party - principal investigator
- University of CopenhagenOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.